Carmenta Bioscience, Inc., a Palo Alto-CA-based medical technology company focused on maternal and fetal health, secured over $2M in seed funding.
Co-founded by Drs. Atul Butte and Bruce Ling of Stanford University and led by Dr. Matthew Cooper, President and Chief Executive Officer, Carmenta focuses on advancing maternal and fetal health by applying a systems biology approach to the diagnosis and prediction of preeclampsia (a leading cause of both
preterm birth and maternal and fetal death). The company’s products in development combine proprietary computational algorithms with novel serum protein measurements to classify pregnant mothers at risk for preeclampsia.
Carmenta intends to use the funds to develop and commercialize a new, proprietary test to better diagnose and predict preeclampsia, which is
based on a worldwide, exclusive technology license from Stanford University.
Camille Samuels, managing director at Versant Ventures, will join the company’s Board of Directors as a result of the financing.